Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs have been in high demand in Kazakhstan due to the increasing prevalence of respiratory diseases in the country.
Customer preferences: Bronchodilator drugs are preferred by patients suffering from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. These drugs provide relief by relaxing the muscles in the airways and increasing airflow to the lungs. Patients in Kazakhstan prefer bronchodilator drugs that are easy to use and provide quick relief from symptoms.
Trends in the market: The bronchodilator drugs market in Kazakhstan has been growing steadily due to the increasing prevalence of respiratory diseases in the country. The market has been witnessing a shift towards combination drugs that provide both bronchodilator and anti-inflammatory effects. This trend is driven by the need for more effective treatment options for patients suffering from severe respiratory diseases. Additionally, there has been an increasing focus on the development of long-acting bronchodilators that provide sustained relief from symptoms.
Local special circumstances: Kazakhstan has a high prevalence of respiratory diseases due to factors such as air pollution, smoking, and exposure to occupational hazards. The country has a high smoking rate, which is a major risk factor for respiratory diseases. Additionally, the country has a large population of workers in industries such as mining and oil and gas, who are exposed to dust and other harmful substances that can cause respiratory diseases.
Underlying macroeconomic factors: Kazakhstan has a growing economy, which has led to an increase in healthcare spending in the country. The government has been investing in the development of healthcare infrastructure and improving access to healthcare services. This has led to an increase in demand for bronchodilator drugs in the country. Additionally, the country has a large population of elderly people, who are more susceptible to respiratory diseases. This has also contributed to the growth of the bronchodilator drugs market in Kazakhstan.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
